Genzyme Renagel Trial Will Compare Effect On Mortality With Other Agents
Executive Summary
Genzyme is studying Renagel's effect on cardiac calcification and mortality to support a comparative claim versus other phosphate binders, Genzyme Senior VP-Corporate Affairs Elliott Hillback told the Bear Stearns "virtual" healthcare conference Sept. 24.
You may also be interested in...
Genzyme Renagel Kidney Disease Trials Focus On Moderate/Severe Patients
Genzyme's Renagel development program in chronic kidney disease will initially focus on moderate to severe patients who are under the care of a nephrologist
Genzyme Renagel Kidney Disease Trials Focus On Moderate/Severe Patients
Genzyme's Renagel development program in chronic kidney disease will initially focus on moderate to severe patients who are under the care of a nephrologist
Biologics Approval Time Drops To 19 Months In 2001
The average approval time for a new therapeutic/ vaccine biologic application in 2001 was 19 months, a five-month improvement over 2000